Clinical trial
An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination
NCT00044668 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination
- Lead sponsor
- AstraZeneca
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2002
- Completion date
- September 30, 2005
- Enrollment
- 155 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.